From an old remedy to a magic bullet: Molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

Blood

Volumn 117, Issue 24, 2011, Pages 6425-6437

  Chen, Sai Juan ^a,b   Zhou, Guang Biao ^c   Zhang, Xiao Wei ^a,b   Mao, Jian Hua ^a   De Thé, Hugues ^d   Chen, Zhu ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b Shanghai Jiao Tong University   (China)

^c INSTITUTE OF ZOOLOGY   (China)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; ARSENIC TRIOXIDE; DASATINIB; DISULFIDE; IMATINIB; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; THIOL; ZIDOVUDINE; ZINC FINGER PROTEIN;

APOPTOSIS; AUTOPHAGY; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; HUMAN; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA REMISSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; UBIQUITINATION; ZINC FINGER MOTIF;

EID: 79959473062     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-283598     Document Type: Review

References (183)

1. National Research Council (NRC). Arsenic. Washington, DC: The National Academies Press; 1977.
2. Wolfe-Simon F, Blum JS, Kulp TR, et al. A bacterium that can grow by using arsenic instead of phosphorus [published online ahead of print December 2, 2010]. Science. doi:10.1126/ science.1197258.
3. Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand. 1957;159(3):189-194.
4. Kumagai Y, Sumi D. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu Rev Pharmacol Toxicol. 2007;47(1):243-262.
5. ISSI Consulting Group. Arsenic Occurrence in Public Drinking Water Supplies. Washington, DC: U.S. Environmental Protection Agency; 2000. EPA publication no. 815-R-00-023.
6. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2(9):705-713. (Pubitemid 37328921)
7. Sharma VK, Sohn M. Aquatic arsenic: toxicity, speciation, transformations, and remediation. Environ Int. 2009;35(4):743-759.
8. Wang JP, Qi L, Moore MR, Ng JC. A review of animal models for the study of arsenic carcinogenesis. Toxicol Lett. 2002;133(1):17-31. (Pubitemid 34655542)
9. Ng JC. Environmental contamination of arsenic and its toxicological impact on humans. Environ Chem. 2005;2(3):146-160. (Pubitemid 41599736)
10. Mann KK, Wallner B, Lossos IS, Miller WH Jr. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs. 2009;18(11):1727-1734.
11. Lin S, Shi Q, Nix FB, et al. A novel S-adenosyl-Lmethionine: arsenic(III) methyltransferase from rat liver cytosol. J Biol Chem. 2002;277(13):10795- 10803. (Pubitemid 34952833)
12. Wood TC, Salavagionne OE, Mukherjee B, et al. Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem. 2006;281(11): 7364-7373. (Pubitemid 43847506)
13. Del Razo LM, Styblo M, Cullen WR, Thomas DJ. Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol.2001;174(3) :282-293. (Pubitemid 32747839)
14. Kitchin KT. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol. 2001;172(3):249-261. (Pubitemid 32406033)
15. Chen GQ, Zhou L, Styblo M, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 2003;63(8):1853-1859. (Pubitemid 36460848)
16. Styblo M, Del Razo LM, Vega L, et al. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol. 2000;74(6):289-299. (Pubitemid 30660931)
17. Smith AH, Hopenhayn-Rich C, Bates MN, et al. Cancer risks from arsenic in drinking water. Environ Health Perspect. 1992;97:259-267.
18. Hughes MF. Arsenic toxicity and potential mechanisms of action. Toxicol Lett. 2002;133(1):1-16. (Pubitemid 34655541)
19. Vallee BL, Ulmer DD, Wacker WE. Arsenic toxicology and biochemistry. A M A Arch Ind Health. 1960;21:132-151.
20. The World Bank. Environment and Social Unit-South Asia Region. Towards a More Effective Operational Response. Arsenic Contamination of Groundwater in South and East Asian Countries. Vol II technical report. Washington, DC: The World Bank; 2005.
21. Aposhian HV, Aposhian MM. Arsenic toxicology: five questions. Chem Res Toxicol. 2006;19(1): 1-15. (Pubitemid 43185456)
22. Teixeira MC, Ciminelli VST, Dantas MSS, Diniz SF, Duarte HA. Raman spectroscopy and DFT calculations of As(III) complexation with a cysteine-rich biomaterial. J Colloid Interface Sci. 2007;315(1):128-134. (Pubitemid 47410034)
23. Schuliga M, Chouchane S, Snow ET. Upregulation of glutathione-related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. Toxicol Sci. 2002;70(2):183-192. (Pubitemid 36013651)
24. Zhou X, Sun H, Ellen TP, Chen H, Costa M. Arsenite alters global histone H3 methylation. Carcinogenesis. 2008;29(9):1831-1836.
25. Andrew AS, Mason RA, Memoli V, Duell EJ. Arsenic activates EGFR pathway signaling in the lung. Toxicol Sci. 2009;109(2):350-357.
26. Cavigelli M, Li WW, Lin A, et al. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 1996;15(22): 6269-6279. (Pubitemid 26397900)
27. He X, Ma Q. Critical cysteine residues of Kelchlike ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2. J Pharmacol Exp Ther. 2010; 332(1):66-75.
28. Pi J, Qu W, Reece JM, Kumagai Y, Waalkes MP. Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide. Exp Cell Res. 2003;290(2): 234-245. (Pubitemid 37272168)
29. Hughes MF. Biomarkers of exposure: a case study with inorganic arsenic. Environ Health Perspect. 2006;114(11):1790-1796. (Pubitemid 44718288)
30. The Inner Canon of Emperor Huang (Originally published in the Spring and Autumn and the Warring States Periods of China, 722 BC-221 BC). Beijing, China: Chinese Medical Ancient Books Publishing House; 2003.
31. Huang B, Wang Y. Thousand Formulas and Thousand Herbs of Traditional Chinese Medicine. Harbin, China: Heilongjiang Education Press; 993.
32. Li SZ. The Compendium of Materia Medica (Originally published in the Ming Dynasty of China, 1578). Beijing, China: People's Medical Publishing House; 1982.
33. Jolliffe DM. A history of the use of arsenicals in man. J R Soc Med. 1993;86(5):287-289. (Pubitemid 23142231)
34. Sears DA. History of the treatment of chronic myelocytic leukemia. Am J Med Sci. 1988;296(2): 85-86.
35. Zhou G, Zhang J, Wang Z, Chen S, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil Trans R Soc B. 2007;362(1482):959-971. (Pubitemid 47056795)
36. Degos L. The history of acute promyelocytic leukaemia. Br J Haematol. 2003;122(4):539-553. (Pubitemid 36995210)
37. Zhou GB, Zhao WL, Wang ZY, Chen SJ, Chen Z. Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med. 2005;2(1):33-38.
38. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008; 111(5):2505-2515.
39. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxidebased therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(9):3342-3347.
40. Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41(4):489-496.
41. Huang ME, Ye YC, Chen SR, et al. Use of alltrans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572.
42. Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115(9):1690-1696.
43. Creutzig U, Zimmermann M, Dworzak M, et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol. 2010;149(3):399-409.
44. Wang ZY. Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. Hematology Am Soc Hematol Educ Program. 2003;1-13.
45. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101(15):5328-5335. (Pubitemid 38481160)
46. Jeanne M, Lallemand-Breitenbach V, Ferhi O, et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010;18(1):88-98.
47. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PMLRARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A. 2000;97(18):10173-10178.
48. Koken MH, Daniel MT, Gianni M, et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/ RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene. 1999;18(4):1113-1118. (Pubitemid 29086289)
49. Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995;85(4):1083-1094.
50. Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 1993;12(3):1161-1167. (Pubitemid 23095865)
51. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775-783.
52. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med. 1992;12:170-171.
53. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315-3324. (Pubitemid 29536124)
54. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354-3360.
55. Shigeno K, Naito K, Sahara N, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol. 2005;82(3):224-229. (Pubitemid 41552328)
56. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852-3860. (Pubitemid 32880064)
57. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010; 28(24):3866-3871.
58. Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115(9):1697-1702.
59. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751-3757.
60. Dai CW, Zhang GS, Shen JK, et al. Use of alltrans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol. 2009;121(1):1-8.
61. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17(1):131-134. (Pubitemid 43033852)
62. Wu T, Zhao J, Jiang B, et al. Tetra-arsenic tetrasulfide containing triple-agent regimen as the first line therapy for acute promyelocytic leukemia: expeditiously consecutive complete remission and improved disease-free survival [abstract]. Blood. 2007;110(11):Abstract 591.
63. Huang SL, Guo AX, Xiang Y, et al. Clinical study on the treatment of acute promyelocytic leukemia with Composite Indigo Naturalis tablets. Chin J Hematol. 1995;16:26-28.
64. Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetrasulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99(9):3136-3143. (Pubitemid 34525290)
65. Wang K, Wang P, Shi J, et al. PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell. 2010;17(2):186-197.
66. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93(10):3167-3215. (Pubitemid 29220886)
67. Kamashev D, Vitoux D, de The H. PML-RARARXR oligomers mediate retinoid and rexinoid/ cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med. 2004;199(8):1163-1174. (Pubitemid 38619912)
68. Zhu J, Koken MH, Quignon F, et al. Arsenicinduced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94(8): 3978-3983. (Pubitemid 27180484)
69. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88(3):1052-1061. (Pubitemid 26333331)
70. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dosedependent dual effects on APL cells. Blood. 1997; 89(9):3345-3353. (Pubitemid 27229821)
71. Borden KL, Boddy MN, Lally J, et al. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J. 1995;14(7):1532-1541.
72. Borden KL, Lally JM, Martin SR, et al. In vivo and in vitro characterization of the B1 and B2 zincbinding domains from the acute promyelocytic leukemia protooncoprotein PML. Proc Natl Acad Sci U S A. 1996;93(4):1601-1606. (Pubitemid 26075172)
73. Butler JT, Hall LL, Smith KP, Lawrence JB. Changing nuclear landscape and unique PML structures during early epigenetic transitions of human embryonic stem cells. J Cell Biochem. 2009;107(4):609-621.
74. Lallemand-Breitenbach V, de The H. PML nuclear bodies. Cold Spring Harb Perspect Biol. 2010; 2(5):a000661.
75. Luciani JJ, Depetris D, Usson Y, et al. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodeling at the G2 phase. J Cell Sci. 2006; 119(Pt 12):2518-2531. (Pubitemid 44070433)
76. Daniel MT, Koken M, Romagne O, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood. 1993;82(6): 1858-1867. (Pubitemid 23278777)
77. Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PMLor PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10(5):547-555. (Pubitemid 351627374)
78. Lallemand-Breitenbach V, Zhu J, Puvion F, et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med. 2001;193(12):1361-1371. (Pubitemid 32565965)
79. Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RAR{alpha} oncoprotein by directly binding PML. Science. 2010; 328(5975):240-243.
80. Zhu J, Zhou J, Peres L, et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell. 2005;7(2):143-153. (Pubitemid 40248340)
81. Chen Z, Zhao WL, Shen ZX, et al. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological. Curr Top Microbiol Immunol. 2007; 313:129-144. (Pubitemid 47400336)
82. Tatham MH, Geoffroy MC, Shen L, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol. 2008;10(5):538-546. (Pubitemid 351627373)
83. Mao JH, Sun XY, Liu JX, et al. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2010;107(50):21683-21688.
84. Lu J, Chew EH, Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A. 2007; 104(30):12288-12293. (Pubitemid 47206130)
85. Rodriguez VM, Del Razo LM, Limon-Pacheco JH, et al. Glutathione reductase inhibition and methylated arsenic distribution in Cd1 mice brain and liver. Toxicol Sci. 2005;84(1):157-166. (Pubitemid 40340283)
86. Chang KN, Lee TC, Tam MF, et al. Identification of galectin I and thioredoxin peroxidase II as two arsenic-binding proteins in Chinese hamster ovary cells. Biochem J. 2003;371(Pt 2):495-503. (Pubitemid 36547633)
87. Donoghue N, Yam PT, Jiang XM, Hogg PJ. Presence of closely spaced protein thiols on the surface of mammalian cells. Protein Sci. 2000;9(12): 2436-2445. (Pubitemid 32105726)
88. Ngu TT, Stillman MJ. Arsenic binding to human metallothionein. J Am Chem Soc. 2006;128(38): 12473-12483. (Pubitemid 44476638)
89. He X, Ma Q. Induction of metallothionein I by arsenic via metal-activated transcription factor 1: critical role of C-terminal cysteine residues in arsenic sensing. J Biol Chem. 2009;284(19):12609-12621.
90. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999;59(4):776-780. (Pubitemid 29086725)
91. Zhang X, Yang F, Shim JY, et al. Identification of arsenic-binding proteins in human breast cancer cells. Cancer Lett. 2007;255(1):95-106. (Pubitemid 47212608)
92. Menzel DB, Hamadeh HK, Lee E, et al. Arsenic binding proteins from human lymphoblastoid cells. Toxicol Lett. 1999;105(2):89-101. (Pubitemid 29132759)
93. Izdebska M, Grzanka A, Ostrowski M, Zuryn A, Grzanka D. Effect of arsenic trioxide (Trisenox) on actin organization in K-562 erythroleukemia cells. Folia Histochem Cytobiol. 2009;47(3):453-459.
94. Yoda A, Toyoshima K, Watanabe Y, et al. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J Biol Chem. 2008;283(27):18969-18979.
95. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000;275(46): 36062-36066.
96. Lin CH, Huang CF, Chen WY, et al. Characterization of the interaction of galectin-1 with sodium arsenite. Chem Res Toxicol. 2006;19(3):469-474.
97. Lu M, Wang H, Li XF, et al. Binding of dimethylarsinous acid to cys-13alpha of rat hemoglobin is responsible for the retention of arsenic in rat blood. Chem Res Toxicol. 2007;20(1):27-37. (Pubitemid 46220152)
98. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5(4):311-321. (Pubitemid 40488636)
99. Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 2008; 14(12):1333-1342.
100. Zheng X, Seshire A, Ruster B, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RAR{alpha}-positive leukemic stem cells. Haematologica. 2007;92(3): 323-331. (Pubitemid 350143541)
101. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23(1):15-25. (Pubitemid 44950185)
102. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171-3179.
103. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453(7198):1072-1078. (Pubitemid 351871736)
104. Zhen Y, Zhao S, Li Q, Li Y, Kawamoto K. Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett. 2010;292(1):64-72.
105. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;107(30):13432-13437.
106. Mathieu J, Besancon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Ann N Y Acad Sci. 2006;1090:203-208. (Pubitemid 47092124)
107. Yu J, Qian H, Li Y, et al. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecol Oncol. 2007;106(2):400-406. (Pubitemid 47096659)
108. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62(14):3893-3903. (Pubitemid 34792653)
109. Li J, Chen P, Sinogeeva N, et al. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem. 2002;277(51): 49504-49510. (Pubitemid 36014387)
110. Davison K, Mann KK, Miller WH Jr. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002; 39(2 suppl 1):3-7.
111. Pan XY, Chen GQ, Cai L, Buscemi S, Fu GH. Anion exchanger 2 mediates the action of arsenic trioxide. Br J Haematol. 2006;134(5):491-499. (Pubitemid 44141715)
112. Bernardini S, Nuccetelli M, Noguera NI, et al. Role of GSTP1-1 in mediating the effect of As2O3 in the acute promyelocytic leukemia cell line NB4. Ann Hematol. 2006;85(10):681-687. (Pubitemid 44255038)
113. Chou WC, Chen HY, Yu SL, et al. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005;106(1):304-310.
114. Glienke W, Chow KU, Bauer N, Bergmann L. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma. 2006;47(8):1629-1638. (Pubitemid 44364031)
115. Joe Y, Jeong JH, Yang S, et al. ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J Biol Chem. 2006;281(39):28764-28771. (Pubitemid 44507019)
116. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol. 1998;177(2):324-333.
117. Ninomiya M, Kajiguchi T, Yamamoto K, et al. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica. 2006;91(11):1571-1572. (Pubitemid 44736130)
118. Isakson P, Bjoras M, Boe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood. 2010; 116(13):2324-2331.
119. Goussetis DJ, Altman JK, Glaser H, et al. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem. 2010;285(39):29989-29997.
120. Jing Y, Wang L, Xia L, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 2001;97(1):264-269. (Pubitemid 32061269)
121. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999; 189(7):1043-1052. (Pubitemid 29169821)
122. Leung J, Pang A, Yuen WH, Kwong YL, Tse EWC. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 2007;109(2):740-746. (Pubitemid 46105976)
123. Guillemin MC, Raffoux E, Vitoux D, et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med. 2002;196(10):1373-1380. (Pubitemid 35375556)
124. Zhu Q, Zhang JW, Zhu HQ, et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood. 2002;99(3): 1014-1022. (Pubitemid 34525566)
125. Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de The H. Therapy-induced PML/ RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res. 2009;15(20):6321-6326.
126. Nasr R, de The H. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Int J Hematol. 2010;91(5):742-747.
127. Zhao Q, Tao J, Zhu Q, et al. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia. 2004;18(2):285-292. (Pubitemid 38240044)
128. Tarrade A, Bastien J, Bruck N, et al. Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha. Oncogene. 2005;24(14):2277-2288. (Pubitemid 40546687)
129. Pendino F, Flexor M, Delhommeau F, et al. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc Natl Acad Sci U S A. 2001; 98(12):6662-6667. (Pubitemid 32538273)
130. Tarkanyi I, Dudognon C, Hillion J, et al. Retinoid/ arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia. 2005;19(10):1806-1811. (Pubitemid 41486159)
131. Zheng PZ, Wang KK, Zhang QY, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/ apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005;102(21):7653-7658.
132. Liu YF, Zhu YM, Shi ZZ, et al. Long-term follow-up confirms the benefit of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as front line therapy for newly diagnosed acute promyelocytic leukemia [abstract]. Blood. 2006;108(11): Abstract 565.
133. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9): 3469-3473.
134. Wang G, Li W, Cui J, et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol. 2004;22(2):63-71. (Pubitemid 39410010)
135. Formularies for 52 Kinds of Disorders (Originally published in the spring and autumn and the warring states periods of China, 600 BC-400 BC). Reproduced by: Group for Management of the Silk Book in Mawangdui Han Dynasty Tomb. Beijing, China: Culture Relics Press; 1979.
136. The Cooperation Group of Phase II Clinical Trial of Compound Huangdai Tablet. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol. 2006;27:801-804.
137. Xiang Y, Huang SL, Guo A, et al. The influence on long-term survey of the patients with acute promyelocytic leukemia treated with compound huangdai tablets and chemotherapy. Chin J Clin Hematol. 2007;16(5):204-206.
138. Zhou A. Qing-Huang-San (Realgar in combination with Indigo) in treatment of leukemia. Chin J Integr Tradit West Med. 1998;18:582-583.
139. Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A. 2008;105(12):4826-4831. (Pubitemid 351753831)
140. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9): 3065-3074.
141. Chu S, Holtz M, Gupta M, Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34α cells. Blood. 2004;103(8):3167-3174. (Pubitemid 38451695)
142. Piloto O, Wright M, Brown P, et al. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 2007;109(4):1643-1652. (Pubitemid 46239599)
143. Altman JK, Yoon P, Katsoulidis E, et al. Regulatory effects of mammalian target of rapamycinmediated signals in the generation of arsenic trioxide responses. J Biol Chem. 2008;283(4): 1992-2001.
144. Hayakawa F, Privalsky ML. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell. 2004;5(4):389-401. (Pubitemid 38482074)
145. Lunghi P, Tabilio A, Lo-Coco F, Pelicci PG, Bonati A. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia. 2005;19(2): 234-244. (Pubitemid 40220588)
146. Lunghi P, Costanzo A, Levrero M, Bonati A. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. Blood. 2004;104(2):519-525. (Pubitemid 38900036)
147. Lunghi P, Costanzo A, Salvatore L, et al. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood. 2006;107(11):4549-4553. (Pubitemid 43801384)
148. Lunghi P, Giuliani N, Mazzera L, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood. 2008;112(6):2450-2462.
149. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172-183. (Pubitemid 40314949)
150. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23): 2408-2417. (Pubitemid 44903745)
151. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005; 435(7046):1267-1270. (Pubitemid 40943094)
152. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876-880. (Pubitemid 32743979)
153. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107(11):4532-4539. (Pubitemid 43801382)
154. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003;112(6):831-843. (Pubitemid 36378885)
155. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117-125. (Pubitemid 41039112)
156. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101(2):690-698. (Pubitemid 36077594)
157. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344(14):1038-1042. (Pubitemid 32267973)
158. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908-916. (Pubitemid 44175142)
159. Hu Z, Pan XF, Wu FQ, et al. Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS ONE. 2009;4(7): e6257.
160. O'Dwyer M. Multifaceted approach to the treatment of bcr-abl-positive leukemias. Oncologist. 2002;7(Suppl 1):30-38.
161. Nimmanapalli R, Bali P, O'Bryan E, et al. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res. 2003;63(22):7950-7958. (Pubitemid 37466732)
162. Zhang QY, Mao JH, Liu P, et al. A systems biology understanding of the synergistic effects of arsenic sulfide and imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009;106(9): 3378-3383.
163. Yin T, Wu YL, Sun HP, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004; 104(13):4219-4225. (Pubitemid 39625094)
164. La Rosee P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002;30(7):729-737. (Pubitemid 34831693)
165. Du Y, Wang K, Fang H, et al. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood. 2006;107(4):1582-1590. (Pubitemid 43242397)
166. Berenson JR, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol. 2006;135(2):174-183. (Pubitemid 44401614)
167. Abou-Jawde RM, Reed J, Kelly M, et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol. 2006;23(2):263-272. (Pubitemid 43780310)
168. Wu KL, Beksac M, van Droogenbroeck J, et al. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica. 2006;91(12):1722-1723. (Pubitemid 46032977)
169. Berenson JR, Matous J, Swift RA, et al. A Phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2007;13(6):1762-1768. (Pubitemid 46952943)
170. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/ lymphoma. Hematol J. 2004;5(2):130-134. (Pubitemid 38519262)
171. Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009;113(26): 6528-6532.
172. Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006;24(16):2456-2464. (Pubitemid 46630622)
173. Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006; 24(16):2465-2471. (Pubitemid 46630623)
174. Zheng WL, Zhang GS, Xu YX, et al. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. Leuk Res. 2008;32(2):251-254.
175. Chang JE, Voorhees PM, Kolesar JM, et al. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol. 2009;27(1):11-16.
176. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93(1):278-283. (Pubitemid 29019413)
177. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/ interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 2003;101(11): 4576-4582. (Pubitemid 36857830)
178. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenicinterferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax downregulation and reversal of NF-kappa B activation. Blood. 2000;96(8):2849-2855.
179. El Hajj H, El-Sabban M, Hasegawa H, et al. Therapy-induced selective loss of leukemiainitiating activity in murine adult T cell leukemia. J Exp Med. 2010;207(13):2785-2792.
180. Emadi A, Gore SD. Arsenic trioxide-an old drug rediscovered. Blood Rev. 2007;24(4-5):191-199.
181. Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001;98(2):266-271.
182. Mathews V, George B, Lakshmi KM, et al. Singleagent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006; 107(7):2627-2632.
183. Luesink M, Pennings JLA, Wissink WM, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood. 2009;114(27):5512-5521.